title: Protective Effect of Infliximab Against Carbon Tetrachloride-Induced Hepatotoxicity.
abstract: Carbon tetrachloride (CCl4), a solvent frequently used in industry, can cause acute liver failure and liver fibrosis. Infliximab (Ib), a potent tumor necrosis factor alpha blocker, has a protective effect on the liver. Therefore, we investigated the protective effect of Ib against CCl4-induced acute liver injury. In this study, 24 male Sprague Dawley rats were randomly divided into three groups: the control group (n = 8), the CCl4 group (n = 8), and the CCl4 + Ib group (n = 8). A single dose of 2 mL/kg CCL4 was administered to the CCL4 group. The CCl4 + Ib group was injected with a single dose (7 mg/kg) of Ib 24 h before CCl4 was administered. In the CCl4 group, the serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and the liver tissue levels of transforming growth factor beta 1 (TGF-β1), interleukin 1 beta (IL-1β), and adenosine deaminase (ADA) were significantly higher than the levels of these same substances in the control and CCl4 + Ib groups. The histopathological investigation revealed that although there was excessive liver injury in the CCl4 group, there was reduced injury in the CCl4 + Ib group. In addition, the carbamoyl phosphate synthetase I (CPS-I) and carbonic anhydrase II (CA-II) levels in the CCl4 group were significantly lower than those in the control and CCl4 + Ib groups. The results show that during CCl4-induced hepatotoxicity, Ib prevents liver injury by suppressing TGF-β1 and IL-1β levels, decreasing ADA levels, and regulating CPS-I and CA-II enzyme levels.
authors.affiliation: Department of Pathology, Faculty of Medicine, RecepTayyip Erdogan University, Rize, Turkey.
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Sehitoglu
authors.affiliation: Department of Histology and Embryology, Faculty of Medicine, RecepTayyip Erdogan University, Rize, Turkey.
authors.forename: Levent
authors.initials: L
authors.lastname: Tumkaya
authors.affiliation: Department of Pathology, Faculty of Medicine, RecepTayyip Erdogan University, Rize, Turkey.
authors.forename: Recep
authors.initials: R
authors.lastname: Bedir
authors.affiliation: Department of Surgery, Recep Tayyip Erdogan University, School of Medicine, Rize, Turkey.
authors.forename: Ender
authors.initials: E
authors.lastname: Ozer
authors.affiliation: Department of Biochemistry, Faculty of Medicine, RecepTayyip Erdogan University, Rize, Turkey.
authors.forename: Medine Cumhur
authors.initials: MC
authors.lastname: Cure
authors.affiliation: Department of Histology and Embryology, Faculty of Medicine, RecepTayyip Erdogan University, Rize, Turkey.
authors.forename: Yildiray
authors.initials: Y
authors.lastname: Kalkan
authors.affiliation: Internal Medicine, Kumru State Hospital, Ordu, Turkey.
authors.forename: Suleyman
authors.initials: S
authors.lastname: Yuce
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, RecepTayyip Erdogan University, Rize, Turkey.
authors.forename: Erkan
authors.initials: E
authors.lastname: Cure
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D002251:Carbon Tetrachloride / Q000633:toxicity*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D000069285:Infliximab; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000293:injuries / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012997:Solvents / Q000633:toxicity*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D016207:Cytokines; D012997:Solvents; D000069285:Infliximab; D002251:Carbon Tetrachloride